87S.F ROIVANT SCIENCES
- Market cap
- EUR 26.4B
- P/E
- -
- P/B
- 7.17x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is 87S.F undervalued?
Graham numberThe Graham number of ROIVANT SCIENCES cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ROIVANT SCIENCES fundamental analysis
No fundamental analysis for ROIVANT SCIENCES yet.
ROIVANT SCIENCES stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ROIVANT SCIENCES
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizab…
Full company profileROIVANT SCIENCES financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ROIVANT SCIENCES annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 55.3M | 31.5M | 32.7M | 29.1M | 8.26M | 73.1M |
| Gross Profit | 46.3M | 28.5M | 31.1M | 28.1M | 6.98M | 65.9M |
| Operating Income | -1.21B | -809M | -825M | -1.11B | -1.29B | -1.27B |
| EBITDA | - | -790M | -803M | -1.10B | -1.28B | -1.27B |
| Net Income | -845M | -1.01B | 4.35B | -172M | -300M | -763M |
| EPS | -1.22 | -1.33 | 5.39 | -0.25 | -0.42 | -1.05 |
| Balance Sheet | ||||||
| Total Assets | 2.59B | 2.39B | 7.22B | 5.44B | 5.71B | 4.98B |
| Total Liabilities | 524M | 782M | 774M | 250M | 416M | 4.98B |
| Shareholders' Equity | 1.66B | 1.16B | 5.97B | 4.69B | 4.53B | 4.02B |
| Cash & Short-term Investments | 2.06B | 1.68B | 6.49B | 2.72B | 1.42B | - |
| Cash Flow | ||||||
| Operating Cash Flow | -678M | -843M | -765M | -839M | -750M | 648M |
| Capital Expenditure | 17.4M | 12.7M | 1.38M | 4.60M | 8.21M | 1.25M |
| Free Cash Flow | -695M | -856M | -767M | -844M | -759M | 647M |
| Ratios | ||||||
| ROE | -51.0% | -87.2% | 72.9% | -3.7% | -6.6% | -19.0% |
| ROA | -32.7% | -42.2% | 60.2% | -3.2% | -5.3% | -15.3% |
| Net Profit Margin | -1,528.9% | -3,200.2% | 13,294.2% | -592.0% | -3,629.2% | -1,043.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ROIVANT SCIENCES dividends
ROIVANT SCIENCES has not paid dividends in the last 5 fiscal years.
Who owns ROIVANT SCIENCES
- Insiders 21.26%
- Institutions 78.74%
- Public & others 0.00%
- Shares outstanding 725M
- Free float 584M
ROIVANT SCIENCES company profile
- Company name
- ROIVANT SCIENCES
- Ticker
- 87S.F
- ISIN
- BMG762791017
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 721
- Fiscal year end
- March
- Address
- 50 Broadway, London, United Kingdom, SW1H 0DB
- Phone
- 44 20 7400 3347
- Website
- roivant.com
About ROIVANT SCIENCES
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
ROIVANT SCIENCES management
10- Mr. Matthew GlineCEO & Director · born 1984
- Dr. Eric Venker M.D., Pharm.D.President & CEO of Immunovant · born 1987
- Dr. Mayukh Sukhatme M.D.President, Chief Investment Officer & Director · born 1976
- Dr. Frank M. Torti M.B.A., M.D.President & Vant Chair · born 1979
- Mr. Richard PulikChief Financial Officer · born 1980
- Ms. Jennifer HumesChief Accounting Officer · born 1981
- Mr. Ian RosenblumChief Information Officer
- Mr. Sam KaplanGeneral Counsel
- Ms. Kelly GraffHead of People
- Mr. Alex GasnerExecutive Vice President of Roivant Health